CAR-T Therapy for Autoimmune Diseases: Resetting the Immune System Beyond Cancer Treatment

A therapy developed to treat blood cancers is producing remarkable results in severe autoimmune diseases—complete remissions in conditions once considered incurable. CAR-T cell therapy, which re-engineers a patient’s immune cells to target disease, has moved from oncology into rheumatology with striking early success.

Recent clinical trials show patients with severe lupus achieving drug-free remission after a single CAR-T treatment. Similar results are emerging for other autoimmune conditions including myasthenia gravis, systemic sclerosis, and inflammatory myopathies. The therapy essentially resets the immune system, eliminating the aberrant cells driving autoimmune attack while preserving normal immune function.

This represents a fundamental shift in autoimmune disease treatment—from chronic immunosuppression managing symptoms to potentially curative interventions targeting root causes. Understanding how CAR-T works, what results show so far, and what challenges remain provides insight into what may become a revolutionary approach to autoimmune disease.

The Autoimmune Disease Treatment Problem

Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues. Depending on which tissues are targeted, this causes different conditions—joints in rheumatoid arthritis, insulin-producing cells in type 1 diabetes, the neuromuscular junction in myasthenia gravis, multiple organs in systemic lupus erythematosus (SLE).

Current treatments rely primarily on immunosuppression—drugs that broadly dampen immune function to reduce autoimmune attack. While these medications can be effective, they come with significant drawbacks:

• Increased infection risk from suppressed immunity
• Long-term toxicity affecting kidneys, liver, bone marrow, and other organs
• Incomplete control with disease often progressing despite treatment
• Lifelong medication with associated costs and side effects
• Poor quality of life from both disease symptoms and treatment side effects

Moreover, immunosuppression doesn’t eliminate the underlying cause—the autoreactive immune cells remain. Stop the medication, and disease typically relapses.

What if instead of suppressing the entire immune system, we could selectively eliminate only the cells causing autoimmune disease?

CAR-T Cell Therapy: From Cancer to Autoimmunity

CAR-T (Chimeric Antigen Receptor T-cell) therapy was developed for blood cancers, particularly B-cell leukemias and lymphomas. The approach involves:

1. Collecting T cells (a type of immune cell) from the patient’s blood

2. Genetically engineering these T cells to express a chimeric antigen receptor (CAR) on their surface that recognizes a specific target protein

3. Expanding these modified cells to large numbers in the laboratory

4. Infusing them back into the patient, where they seek out and destroy cells expressing the target protein

For blood cancers, the target is typically CD19—a protein expressed on B cells (a type of immune cell). The CAR-T cells find and eliminate all CD19-positive B cells, including cancerous ones. This has produced remarkable remission rates in patients with otherwise treatment-resistant leukemias and lymphomas.

The leap to autoimmune disease wasn’t obvious initially. But researchers recognized that many autoimmune conditions involve autoreactive B cells producing antibodies against the body’s own tissues. If CAR-T therapy targeting CD19 could eliminate all B cells—both cancerous and autoreactive—it might reset the immune system and resolve autoimmune disease.

The Lupus Breakthrough

Systemic lupus erythematosus is a severe autoimmune disease where the immune system attacks multiple organs—kidneys, heart, lungs, brain, joints, skin, and blood cells. Despite modern treatments, mortality rates remain elevated, and many patients experience progressive organ damage.

Lupus is driven largely by autoreactive B cells producing antibodies against the patient’s own DNA, proteins, and cellular components. These antibodies form immune complexes that deposit in tissues, triggering inflammation and damage.

In 2022, University of Erlangen researchers in Germany reported the first case of CAR-T therapy for severe lupus. The patient had failed all standard treatments and faced life-threatening disease. After a single CAR-T infusion targeting CD19, her lupus went into complete remission—no disease activity, no need for immunosuppressive medications. Over two years later, remission persists.

This prompted larger trials. The University of Chicago, under Dr. James Xu, launched Phase 2 trials enrolling patients with severe lupus who had failed multiple conventional treatments. Early results presented in 2025 are striking:

• 15 patients treated thus far, all with severe, refractory disease
• All patients achieved complete remission of clinical disease activity within 3 months
• Autoantibody levels (anti-DNA antibodies and others) decreased dramatically or became undetectable
• Most patients discontinued all immunosuppressive medications
• Remissions have lasted over a year in the earliest treated patients with no relapses
• Normal B cells eventually recovered, restoring immune function

These aren’t incremental improvements—these are transformative outcomes in patients who had exhausted other options.

Beyond Lupus: Other Autoimmune Conditions

The success in lupus has prompted trials in other B-cell-mediated autoimmune diseases:

Myasthenia Gravis

This condition involves antibodies against the neuromuscular junction, causing progressive muscle weakness. Severe cases require chronic immunosuppression and may progress to respiratory failure.

Initial CAR-T trials in refractory myasthenia gravis show similar dramatic responses—elimination of pathogenic antibodies, restoration of muscle strength, discontinuation of immunosuppressive drugs, and sustained remissions.

Systemic Sclerosis (Scleroderma)

This devastating disease causes progressive fibrosis of skin and internal organs, particularly lungs and kidneys. Treatment options are limited, and prognosis is often poor.

Early CAR-T results show stabilization or even improvement in fibrosis markers and organ function—outcomes rarely seen with conventional treatments.

Inflammatory Myopathies

Conditions like dermatomyositis and polymyositis cause progressive muscle inflammation and weakness. CAR-T therapy has produced remissions in cases resistant to standard immunosuppression.

Future Targets

Research groups are exploring CAR-T for other autoimmune conditions including:

• Pemphigus and pemphigoid (autoimmune blistering diseases)
• Autoimmune hemolytic anemia
• Immune thrombocytopenia
• Potentially type 1 diabetes if treated early enough
• Possibly multiple sclerosis, though this is more complex

Not all autoimmune diseases are primarily B-cell-mediated, so CD19-targeted CAR-T may not work for all conditions. Diseases driven by autoreactive T cells rather than antibody-producing B cells might require different approaches. But for B-cell-mediated autoimmune diseases, the potential appears substantial.

How CAR-T Resets the Immune System

Understanding why CAR-T produces lasting remissions requires examining what happens immunologically:

B Cell Depletion Phase

The CAR-T cells eliminate all CD19-positive B cells—both normal and autoreactive. This includes mature B cells in circulation and tissues, as well as memory B cells that maintain long-term antibody responses.

This depletion is profound—B cells become undetectable in blood and tissues for several months after CAR-T infusion. During this period, patients are immunocompromised and susceptible to infections, requiring monitoring and sometimes preventive antibiotics or immunoglobulin replacement.

Immune Reconstitution

Over 3-6 months, B cells begin recovering from bone marrow precursors. But here’s the crucial part: the new B cells that emerge are naive—they haven’t been shaped by the disease process that originally generated autoreactive clones.

It’s essentially a reboot of the B cell compartment. The autoreactive memory cells are gone, replaced by new B cells with normal, non-autoreactive repertoires.

This is why remissions can persist even after B cells recover—the pathogenic cells driving disease have been eliminated, and the new B cells don’t spontaneously become autoreactive.

Why Don’t Autoreactive Cells Return?

This is perhaps the most interesting question. If genetic and environmental factors predisposed someone to develop autoreactive B cells initially, why don’t they redevelop after the immune system resets?

Several hypotheses exist:

Removal of inflammatory milieu: Autoreactive cells may have developed in a pro-inflammatory environment created by tissue damage and immune activation. Once that environment is cleared by eliminating autoreactive cells, the conditions favoring their redevelopment may not persist.

Epigenetic reset: The new B cells developing from progenitors may not carry the epigenetic modifications that characterized autoreactive clones.

Broken feedback loops: Autoimmune disease can create self-perpetuating inflammatory loops. Breaking these loops through profound B cell depletion may allow the system to reset to a healthy equilibrium.

Stochastic factors: Development of autoreactive cells may involve random events that don’t necessarily repeat just because conditions are similar.

The truth likely involves multiple factors, and we’re still learning why these resets appear so durable.

Safety Profile and Complications

CAR-T therapy isn’t without risks. The most significant complications include:

Cytokine Release Syndrome (CRS)

When CAR-T cells engage their targets and begin rapidly multiplying, they release large amounts of inflammatory cytokines. This can cause high fevers, low blood pressure, respiratory distress, and neurological symptoms.

CRS severity ranges from mild (manageable with supportive care) to severe (requiring ICU-level care). Fortunately, we now have effective treatments—tocilizumab, an IL-6 receptor blocker, can rapidly reverse CRS in most cases.

In autoimmune disease trials, CRS rates appear similar to those in cancer trials—common but usually manageable. Close monitoring in experienced centers is crucial.

Immune Cell-Associated Neurotoxicity (ICANS)

Some patients develop neurological symptoms including confusion, aphasia (language difficulties), seizures, or altered consciousness. ICANS typically occurs days after CRS and is thought to involve cytokine effects on the central nervous system.

Like CRS, ICANS severity varies. Mild cases resolve spontaneously, while severe cases require intensive care and sometimes corticosteroids. Most patients recover completely, though in rare cases, symptoms can persist.

Prolonged Cytopenias

Low blood counts—particularly white blood cells and platelets—can persist for weeks or months after CAR-T. This reflects both the conditioning chemotherapy given before CAR-T infusion and potential effects on bone marrow cells.

Management involves monitoring blood counts, transfusions if needed, and sometimes growth factors to stimulate blood cell production.

Infections

The period of B cell depletion leaves patients vulnerable to certain infections, particularly those requiring antibody responses. Encapsulated bacteria (pneumococcus, Haemophilus) are particular concerns.

Preventive strategies include vaccination before CAR-T (while the immune system can still respond), prophylactic antibiotics, and sometimes immunoglobulin replacement to provide passive antibody protection.

Long-Term Risks

Since CAR-T for autoimmune disease is relatively new, long-term safety data is limited. Theoretical concerns include:

• Secondary malignancies from genetic modification (though this hasn’t materialized in cancer trials with longer follow-up)
• Immune dysregulation from profound immunological reset
• Late relapses as autoreactive cells potentially redevelop

Ongoing monitoring of treated patients will clarify these risks over time.

Who Is a Candidate?

Currently, CAR-T for autoimmune disease is offered only in clinical trials or through compassionate use programs. Eligibility typically requires:

• Severe autoimmune disease causing significant organ damage or life-threatening complications
• Failure of multiple conventional immunosuppressive therapies
• B-cell-mediated disease pathology (makes sense for CD19-targeted CAR-T)
• Adequate organ function to tolerate the treatment
• Willingness to accept risks including hospitalization and potential complications

CAR-T isn’t currently appropriate for newly diagnosed or mild autoimmune disease. The risks and costs make it suitable only when other options have failed. But as experience grows and safety improves, indications may expand.

Cost and Access Challenges

CAR-T therapy is extraordinarily expensive—typically $400,000-$600,000 for cancer treatment when including manufacturing, hospitalization, and complication management. These costs present significant barriers to widespread adoption for autoimmune diseases.

However, several factors may drive costs down:

Manufacturing improvements: As CAR-T production becomes more standardized and automated, costs should decrease.

Allogeneic CAR-T: Using donor cells rather than patient-specific cells could allow mass production, dramatically reducing costs.

Outpatient protocols: As management of complications improves, some patients may not require prolonged hospitalization.

Natural killer (NK) CAR cells: Using NK cells instead of T cells may produce fewer complications and lower costs.

Moreover, if CAR-T produces durable remissions eliminating need for lifelong immunosuppression, the long-term cost-effectiveness improves. Decades of medications, monitoring, and managing complications are expensive—a one-time curative therapy might ultimately save money.

Still, access will remain a challenge, particularly in health systems without resources to offer this treatment. Global health equity concerns are significant.

Alternative Approaches Under Development

CAR-T isn’t the only strategy for resetting the immune system in autoimmune disease:

Natural Killer (NK) Cell Therapies

NK cells are another type of immune cell that can be engineered with CARs. NK-CAR cells may cause fewer severe side effects than T cell-based CAR-T while still effectively eliminating target cells. Several groups are developing NK-CAR approaches for autoimmune diseases.

Bispecific Antibodies

These engineered proteins can simultaneously bind CD19 on B cells and CD3 on T cells, bringing them together to trigger B cell elimination. This avoids the complexity of cell manufacturing but may not produce as profound or durable depletion as CAR-T.

Antigen-Specific Tolerance Induction

Rather than eliminating all B cells, could we specifically tolerize the immune system to autoantigens? Research on antigen-specific immunotherapy aims to induce regulatory immune responses that suppress autoimmunity without compromising overall immune function.

Regulatory T Cell (Treg) Therapy

Tregs suppress excessive immune responses and maintain self-tolerance. Expanding or enhancing patient Tregs might restore immune balance without broad immunosuppression.

These approaches represent different strategies toward the same goal—safely and effectively controlling autoimmune disease without chronic immunosuppression.

The Broader Implications

CAR-T for autoimmune disease exemplifies how cell therapy and immunotherapy are reshaping medicine. We’re moving from small-molecule drugs and biologics toward living therapies—cells engineered to perform specific therapeutic functions.

This shift has profound implications. Living therapies can adapt, amplify, and persist—potentially providing durable benefits from a single administration. But they also introduce new complexity, costs, and safety considerations.

As someone working extensively with regenerative and cellular therapies, I view CAR-T for autoimmune disease as part of a broader evolution toward cell-based medicine. Just as I use mesenchymal stem cells, platelet-rich plasma, and exosomes to treat musculoskeletal conditions, immunologists are using engineered immune cells to treat systemic diseases.

The principles overlap—understanding cellular biology, harnessing natural healing mechanisms, and targeting root causes rather than just managing symptoms.

Conclusion

CAR-T cell therapy has moved from treating blood cancers to producing remarkable remissions in severe autoimmune diseases. Early clinical trials show patients with lupus, myasthenia gravis, and other conditions achieving drug-free remission after a single treatment.

The therapy works by eliminating all B cells—including autoreactive ones—then allowing the immune system to rebuild with a normal, non-autoreactive repertoire. It’s essentially a reset that addresses the root cause rather than suppressing symptoms.

Challenges remain—costs are high, complications can be serious, and long-term data is limited. But for patients with severe, treatment-resistant autoimmune disease, CAR-T represents a potentially transformative option.

As the field advances—with improved safety, reduced costs, and expanded applications—CAR-T may evolve from a last-resort treatment to a mainstream approach for autoimmune diseases. That would represent a fundamental shift in how we treat these conditions, moving from chronic immunosuppression to curative interventions.

We’re witnessing the emergence of a new paradigm in autoimmune disease treatment. The results so far suggest that paradigm has remarkable potential.

---

Dr. Pradeep Albert is a regenerative medicine physician and musculoskeletal radiologist specializing in advanced cellular therapies and longevity science. He is the author of “Exosomes, PRP, and Stem Cells in Musculoskeletal Medicine” and co-author of “Lifespan Decoded: How to Hack Your Biology for a Longer, Healthier Life.”